{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-001137","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.918176+00:00","generated_at":"2026-05-26T08:43:04.810446+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Phio Pharmaceuticals appoints David H. Deming to Board of Directors, effective Feb 19, 2025","bullets":["Board expanded to six members; five of six are independent directors.","Deming will serve on the Nominating Committee immediately.","Over 30 years in investment banking; 27 years at JP Morgan leading Health Group in M&A.","Appointment effective February 19, 2025; term until 2025 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-001137","json":"https://secwatch.observer/filing/0001683168-25-001137.json","markdown":"https://secwatch.observer/filing/0001683168-25-001137.md","text":"https://secwatch.observer/filing/0001683168-25-001137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825001137/0001683168-25-001137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825001137/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T08:43:04.810446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fb00a1965","claim":"David H. Deming was appointed as Director at Phio Pharmaceuticals Corp..","evidence_excerpt":"Effective as of February 19, 2025, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed Mr. David H. Deming to serve on the Board until the 2025 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825001137/0001683168-25-001137-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}